<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35194965</PMID><DateCompleted><Year>2022</Year><Month>04</Month><Day>05</Day></DateCompleted><DateRevised><Year>2022</Year><Month>07</Month><Day>01</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2190-6009</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>2</Issue><PubDate><Year>2022</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Journal of cachexia, sarcopenia and muscle</Title><ISOAbbreviation>J Cachexia Sarcopenia Muscle</ISOAbbreviation></Journal><ArticleTitle>Muscle cells of sporadic amyotrophic lateral sclerosis patients secrete neurotoxic vesicles.</ArticleTitle><Pagination><StartPage>1385</StartPage><EndPage>1402</EndPage><MedlinePgn>1385-1402</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/jcsm.12945</ELocationID><Abstract><AbstractText Label="BACKGROUND">The cause of the motor neuron (MN) death that drives terminal pathology in amyotrophic lateral sclerosis (ALS) remains unknown, and it is thought that the cellular environment of the MN may play a key role in MN survival. Several lines of evidence implicate vesicles in ALS, including that extracellular vesicles may carry toxic elements from astrocytes towards MNs, and that pathological proteins have been identified in circulating extracellular vesicles of sporadic ALS patients. Because MN degeneration at the neuromuscular junction is a feature of ALS, and muscle is a vesicle-secretory tissue, we hypothesized that muscle vesicles may be involved in ALS pathology.</AbstractText><AbstractText Label="METHODS">Sporadic ALS patients were confirmed to be ALS according to El Escorial criteria and were genotyped to test for classic gene mutations associated with ALS, and physical function was assessed using the ALSFRS-R score. Muscle biopsies of either mildly affected deltoids of ALS patients (n&#xa0;=&#xa0;27) or deltoids of aged-matched healthy subjects (n&#xa0;=&#xa0;30) were used for extraction of muscle stem cells, to perform immunohistology, or for electron microscopy. Muscle stem cells were characterized by immunostaining, RT-qPCR, and transcriptomic analysis. Secreted muscle vesicles were characterized by proteomic analysis, Western blot, NanoSight, and electron microscopy. The effects of muscle vesicles isolated from the culture medium of ALS and healthy myotubes were tested on healthy human-derived iPSC MNs and on healthy human myotubes, with untreated cells used as controls.</AbstractText><AbstractText Label="RESULTS">An accumulation of multivesicular bodies was observed in muscle biopsies of sporadic ALS patients by immunostaining and electron microscopy. Study of muscle biopsies and biopsy-derived denervation-na&#xef;ve differentiated muscle stem cells (myotubes) revealed a consistent disease signature in ALS myotubes, including intracellular accumulation of exosome-like vesicles and disruption of RNA-processing. Compared with vesicles from healthy control myotubes, when administered to healthy MNs the vesicles of ALS myotubes induced shortened, less branched neurites, cell death, and disrupted localization of RNA and RNA-processing proteins. The RNA-processing protein FUS and a majority of its binding partners were present in ALS muscle vesicles, and toxicity was dependent on the expression level of FUS in recipient cells. Toxicity to recipient MNs was abolished by anti-CD63 immuno-blocking of vesicle uptake.</AbstractText><AbstractText Label="CONCLUSIONS">ALS muscle vesicles are shown to be toxic to MNs, which establishes the skeletal muscle as a potential source of vesicle-mediated toxicity in ALS.</AbstractText><CopyrightInformation>&#xa9; 2022 The Authors. Journal of Cachexia, Sarcopenia and Muscle published by John Wiley &amp; Sons Ltd on behalf of Society on Sarcopenia, Cachexia and Wasting Disorders.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Le Gall</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Northern Ireland Center for Stratified Medicine, Biomedical Sciences Research Institute, Londonderry, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sorbonne Universit&#xe9;, Institut National de la Sant&#xe9; et de la Recherche M&#xe9;dicale, Association Institut de Myologie, Centre de Recherche en Myologie, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duddy</LastName><ForeName>William J</ForeName><Initials>WJ</Initials><AffiliationInfo><Affiliation>Northern Ireland Center for Stratified Medicine, Biomedical Sciences Research Institute, Londonderry, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martinat</LastName><ForeName>Cecile</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>I-Stem, INSERM/UEVE UMR 861, I-STEM, AFM, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mariot</LastName><ForeName>Virginie</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>NIHR Biomedical Research Centre, University College London, Great Ormond Street Institute of Child Health and Great Ormond Street Hospital NHS Trust, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Connolly</LastName><ForeName>Owen</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Northern Ireland Center for Stratified Medicine, Biomedical Sciences Research Institute, Londonderry, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Milla</LastName><ForeName>Vanessa</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Northern Ireland Center for Stratified Medicine, Biomedical Sciences Research Institute, Londonderry, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Anakor</LastName><ForeName>Ekene</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Northern Ireland Center for Stratified Medicine, Biomedical Sciences Research Institute, Londonderry, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ouandaogo</LastName><ForeName>Zamalou G</ForeName><Initials>ZG</Initials><AffiliationInfo><Affiliation>Sorbonne Universit&#xe9;, Institut National de la Sant&#xe9; et de la Recherche M&#xe9;dicale, Association Institut de Myologie, Centre de Recherche en Myologie, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Millecamps</LastName><ForeName>Stephanie</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Inserm U1127, CNRS UMR7225, Sorbonne Universit&#xe9;s, UPMC Univ, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lain&#xe9;</LastName><ForeName>Jeanne</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Sorbonne Universit&#xe9;, Institut National de la Sant&#xe9; et de la Recherche M&#xe9;dicale, Association Institut de Myologie, Centre de Recherche en Myologie, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vijayakumar</LastName><ForeName>Udaya Geetha</ForeName><Initials>UG</Initials><AffiliationInfo><Affiliation>Northern Ireland Center for Stratified Medicine, Biomedical Sciences Research Institute, Londonderry, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Knoblach</LastName><ForeName>Susan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Genetic Medicine, Children's National Medical Center, George Washington University, Washington, DC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Raoul</LastName><ForeName>Cedric</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>The Neuroscience Institute of Montpellier, Inserm UMR1051, Univ Montpellier, Saint Eloi Hospital, Montpellier, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lucas</LastName><ForeName>Olivier</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>The Neuroscience Institute of Montpellier, Inserm UMR1051, Univ Montpellier, Saint Eloi Hospital, Montpellier, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Loeffler</LastName><ForeName>Jean Philippe</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>M&#xe9;canismes Centraux et P&#xe9;riph&#xe9;riques de la Neurod&#xe9;g&#xe9;n&#xe9;rescence, Universit&#xe9; de Strasbourg, INSERM UMR_S 1118, Strasbourg, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bede</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Computational Neuroimaging Group, Academic Unit of Neurology, Trinity College Dublin, Dublin, Ireland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CNRS, INSERM, Laboratoire d'Imagerie Biom&#xe9;dicale, Sorbonne Universit&#xe9;, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>APHP, D&#xe9;partement de Neurologie, H&#xf4;pital Piti&#xe9;-Salp&#xea;tri&#xe8;re, Centre r&#xe9;f&#xe9;rent SLA, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Behin</LastName><ForeName>Anthony</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>APHP, Centre de R&#xe9;f&#xe9;rence des Maladies Neuromusculaires Nord/Est/Ile de France, Institut de Myologie, H&#xf4;pital Piti&#xe9;-Salp&#xea;tri&#xe8;re, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blasco</LastName><ForeName>Helene</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Laboratoire de Biochimie et Biologie Mol&#xe9;culaire, H&#xf4;pital Bretonneau, CHRU de Tours, Tours, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bruneteau</LastName><ForeName>Gaelle</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Sorbonne Universit&#xe9;, Institut National de la Sant&#xe9; et de la Recherche M&#xe9;dicale, Association Institut de Myologie, Centre de Recherche en Myologie, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>APHP, D&#xe9;partement de Neurologie, H&#xf4;pital Piti&#xe9;-Salp&#xea;tri&#xe8;re, Centre r&#xe9;f&#xe9;rent SLA, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Del Mar Amador</LastName><ForeName>Maria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>APHP, D&#xe9;partement de Neurologie, H&#xf4;pital Piti&#xe9;-Salp&#xea;tri&#xe8;re, Centre r&#xe9;f&#xe9;rent SLA, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Devos</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>INSERM U1171, Pharmacologie M&#xe9;dicale &amp; Neurologie Universit&#xe9;, Facult&#xe9; de M&#xe9;decine, CHU de Lille, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Henriques</LastName><ForeName>Alexandre</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>M&#xe9;canismes Centraux et P&#xe9;riph&#xe9;riques de la Neurod&#xe9;g&#xe9;n&#xe9;rescence, Universit&#xe9; de Strasbourg, INSERM UMR_S 1118, Strasbourg, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hesters</LastName><ForeName>Adele</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>APHP, D&#xe9;partement de Neurologie, H&#xf4;pital Piti&#xe9;-Salp&#xea;tri&#xe8;re, Centre r&#xe9;f&#xe9;rent SLA, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lacomblez</LastName><ForeName>Lucette</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>CNRS, INSERM, Laboratoire d'Imagerie Biom&#xe9;dicale, Sorbonne Universit&#xe9;, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>APHP, D&#xe9;partement de Neurologie, H&#xf4;pital Piti&#xe9;-Salp&#xea;tri&#xe8;re, Centre r&#xe9;f&#xe9;rent SLA, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Laforet</LastName><ForeName>Pascal</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>D&#xe9;partement de Neurologie, Centre de R&#xe9;f&#xe9;rence Maladies Neuromusculaires Paris-Est, H&#xf4;pital Raymond-Poincar&#xe9;, Garches, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Langlet</LastName><ForeName>Timothee</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>APHP, D&#xe9;partement de Neurologie, H&#xf4;pital Piti&#xe9;-Salp&#xea;tri&#xe8;re, Centre r&#xe9;f&#xe9;rent SLA, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leblanc</LastName><ForeName>Pascal</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Laboratory of Molecular Biology of the Cell, Ecole Normale Sup&#xe9;rieure de Lyon, Lyon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Le Forestier</LastName><ForeName>Nadine</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>APHP, D&#xe9;partement de Neurologie, H&#xf4;pital Piti&#xe9;-Salp&#xea;tri&#xe8;re, Centre r&#xe9;f&#xe9;rent SLA, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maisonobe</LastName><ForeName>Thierry</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>APHP, D&#xe9;partement de Neurologie, H&#xf4;pital Piti&#xe9;-Salp&#xea;tri&#xe8;re, Centre r&#xe9;f&#xe9;rent SLA, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meininger</LastName><ForeName>Vincent</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>H&#xf4;pital des Peupliers, Ramsay G&#xe9;n&#xe9;rale de Sant&#xe9;, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Robelin</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>M&#xe9;canismes Centraux et P&#xe9;riph&#xe9;riques de la Neurod&#xe9;g&#xe9;n&#xe9;rescence, Universit&#xe9; de Strasbourg, INSERM UMR_S 1118, Strasbourg, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salachas</LastName><ForeName>Francois</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>APHP, D&#xe9;partement de Neurologie, H&#xf4;pital Piti&#xe9;-Salp&#xea;tri&#xe8;re, Centre r&#xe9;f&#xe9;rent SLA, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stojkovic</LastName><ForeName>Tanya</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>APHP, Centre de R&#xe9;f&#xe9;rence des Maladies Neuromusculaires Nord/Est/Ile de France, Institut de Myologie, H&#xf4;pital Piti&#xe9;-Salp&#xea;tri&#xe8;re, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Querin</LastName><ForeName>Giorgia</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>CNRS, INSERM, Laboratoire d'Imagerie Biom&#xe9;dicale, Sorbonne Universit&#xe9;, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>APHP, D&#xe9;partement de Neurologie, H&#xf4;pital Piti&#xe9;-Salp&#xea;tri&#xe8;re, Centre r&#xe9;f&#xe9;rent SLA, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dumonceaux</LastName><ForeName>Julie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>NIHR Biomedical Research Centre, University College London, Great Ormond Street Institute of Child Health and Great Ormond Street Hospital NHS Trust, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Butler Browne</LastName><ForeName>Gillian</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Sorbonne Universit&#xe9;, Institut National de la Sant&#xe9; et de la Recherche M&#xe9;dicale, Association Institut de Myologie, Centre de Recherche en Myologie, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gonz&#xe1;lez De Aguilar</LastName><ForeName>Jose-Luis</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>M&#xe9;canismes Centraux et P&#xe9;riph&#xe9;riques de la Neurod&#xe9;g&#xe9;n&#xe9;rescence, Universit&#xe9; de Strasbourg, INSERM UMR_S 1118, Strasbourg, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duguez</LastName><ForeName>Stephanie</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-6510-5426</Identifier><AffiliationInfo><Affiliation>Northern Ireland Center for Stratified Medicine, Biomedical Sciences Research Institute, Londonderry, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pradat</LastName><ForeName>Pierre Francois</ForeName><Initials>PF</Initials><AffiliationInfo><Affiliation>Northern Ireland Center for Stratified Medicine, Biomedical Sciences Research Institute, Londonderry, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CNRS, INSERM, Laboratoire d'Imagerie Biom&#xe9;dicale, Sorbonne Universit&#xe9;, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>APHP, D&#xe9;partement de Neurologie, H&#xf4;pital Piti&#xe9;-Salp&#xea;tri&#xe8;re, Centre r&#xe9;f&#xe9;rent SLA, Paris, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT02360891</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>259867</GrantID><Agency>European Community's Health Seventh Framework Programme</Agency><Country/></Grant><Grant><Agency>Ulster University</Agency><Country/></Grant><Grant><Agency>Northern Ireland Public Health Agency</Agency><Country/></Grant><Grant><Agency>European Union Regional Development Fund</Agency><Country/></Grant><Grant><Agency>ARsLA</Agency><Country/></Grant><Grant><Agency>Target-ALS</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>02</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>J Cachexia Sarcopenia Muscle</MedlineTA><NlmUniqueID>101552883</NlmUniqueID><ISSNLinking>2190-5991</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057026" MajorTopicYN="Y">Induced Pluripotent Stem Cells</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D032342" MajorTopicYN="N">Muscle Cells</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D040901" MajorTopicYN="N">Proteomics</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cell-cell communication</Keyword><Keyword MajorTopicYN="N">MND</Keyword><Keyword MajorTopicYN="N">Secreted vesicles</Keyword><Keyword MajorTopicYN="N">sporadic ALS</Keyword></KeywordList><CoiStatement>The authors declare that they have no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>11</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>11</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>1</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>2</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>4</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>2</Month><Day>23</Day><Hour>5</Hour><Minute>38</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35194965</ArticleId><ArticleId IdType="pmc">PMC8978001</ArticleId><ArticleId IdType="doi">10.1002/jcsm.12945</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Brown RH, Al&#x2010;Chalabi A. Amyotrophic lateral sclerosis. N Engl J Med 2017;377:1602&#x2013;1602, 1172.</Citation><ArticleIdList><ArticleId IdType="pubmed">29045202</ArticleId></ArticleIdList></Reference><Reference><Citation>Vijayakumar UG, Milla V, Cynthia Stafford MY, Bjourson AJ, Duddy W, Duguez SM&#x2010;R. A systematic review of suggested molecular strata, biomarkers and their tissue sources in ALS. Front Neurol 2019;10:400.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6527847</ArticleId><ArticleId IdType="pubmed">31139131</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Gall L, Anakor E, Connolly O, Vijayakumar UG, Duddy WJ, Duguez S. Molecular and cellular mechanisms affected in ALS. J Pers Med 2020;10:101.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7564998</ArticleId><ArticleId IdType="pubmed">32854276</ArticleId></ArticleIdList></Reference><Reference><Citation>Cappello V, Francolini M. Neuromuscular junction dismantling in amyotrophic lateral sclerosis. Int J Mol Sci 2017;18:2092.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5666774</ArticleId><ArticleId IdType="pubmed">28972545</ArticleId></ArticleIdList></Reference><Reference><Citation>Rizzo F, Riboldi G, Salani S, Nizzardo M, Simone C, Corti S, et al. Cellular therapy to target neuroinflammation in amyotrophic lateral sclerosis. Cell Mol Life Sci 2014;71:999&#x2013;1015.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3928509</ArticleId><ArticleId IdType="pubmed">24100629</ArticleId></ArticleIdList></Reference><Reference><Citation>Scekic&#x2010;Zahirovic J, El OH, Mersmann S, Drenner K, Wagner M, Sun Y, et al. Motor neuron intrinsic and extrinsic mechanisms contribute to the pathogenesis of FUS&#x2010;associated amyotrophic lateral sclerosis. Acta Neuropathol 2017;133:887&#x2013;906.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5427169</ArticleId><ArticleId IdType="pubmed">28243725</ArticleId></ArticleIdList></Reference><Reference><Citation>Dirren E, Aebischer J, Rochat C, Towne C, Schneider BL, Aebischer P. SOD1 silencing in motoneurons or glia rescues neuromuscular function in ALS mice. Ann Clin Transl Neurol 2015;2:167&#x2013;184.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4338957</ArticleId><ArticleId IdType="pubmed">25750921</ArticleId></ArticleIdList></Reference><Reference><Citation>Ilieva H, Polymenidou M, Cleveland DW. Non&#x2010;cell autonomous toxicity in neurodegenerative disorders: ALS and beyond. J Cell Biol 2009;187:761&#x2013;772.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2806318</ArticleId><ArticleId IdType="pubmed">19951898</ArticleId></ArticleIdList></Reference><Reference><Citation>Duguez S, Duddy W, Johnston H, Lain&#xe9; J, Le Bihan MCMC, Brown KJKJ, et al. Dystrophin deficiency leads to disturbance of LAMP1&#x2010;vesicle&#x2010;associated protein secretion. Cell Mol Life Sci 2013;70:2159&#x2013;2174.</Citation><ArticleIdList><ArticleId IdType="pubmed">23344255</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Bihan M&#x2010;C, Bigot A, Jensen SS, Dennis J, Rogowska&#x2010;Wrzesinska A, Lain&#xe9; J, et al. In&#x2010;depth analysis of the secretome identifies three major independent secretory pathways in differentiating human myoblasts. J Proteomics 2012;77:344&#x2013;356.</Citation><ArticleIdList><ArticleId IdType="pubmed">23000592</ArticleId></ArticleIdList></Reference><Reference><Citation>Ciregia F, Urbani A, Palmisano G. Extracellular vesicles in brain tumors and neurodegenerative diseases. Front Mol Neurosci 2017;10:276.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5583211</ArticleId><ArticleId IdType="pubmed">28912682</ArticleId></ArticleIdList></Reference><Reference><Citation>Soria FN, Pampliega O, Bourdenx M, Meissner WG, Bezard E, Dehay B. Exosomes, an unmasked culprit in neurodegenerative diseases. Front Neurosci 2017;11:26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5281572</ArticleId><ArticleId IdType="pubmed">28197068</ArticleId></ArticleIdList></Reference><Reference><Citation>Scesa G, Moyano AL, Bongarzone ER, Givogri MI. Port&#x2010;to&#x2010;port delivery: mobilization of toxic sphingolipids via extracellular vesicles. J Neurosci Res 2016;94:1333&#x2013;1340.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5027965</ArticleId><ArticleId IdType="pubmed">27638615</ArticleId></ArticleIdList></Reference><Reference><Citation>Basso M, Pozzi S, Tortarolo M, Fiordaliso F, Bisighini C, Pasetto L, et al. Mutant copper&#x2010;zinc superoxide dismutase (SOD1) induces protein secretion pathway alterations and exosome release in astrocytes: Implications for disease spreading and motor neuron pathology in amyotrophic lateral sclerosis. J Biol Chem 2013;288:15699&#x2013;15711.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3668729</ArticleId><ArticleId IdType="pubmed">23592792</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks BR, Miller RG, Swash M, Munsat TL. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2000;1:293&#x2013;299.</Citation><ArticleIdList><ArticleId IdType="pubmed">11464847</ArticleId></ArticleIdList></Reference><Reference><Citation>Millecamps S, Boill&#xe9;e S, Le Ber I, Seilhean D, Teyssou E, Giraudeau M, et al. Phenotype difference between ALS patients with expanded repeats in C9ORF72 and patients with mutations in other ALS&#x2010;related genes. J Med Genet 2012;49:258&#x2013;263.</Citation><ArticleIdList><ArticleId IdType="pubmed">22499346</ArticleId></ArticleIdList></Reference><Reference><Citation>Lattante S, Millecamps S, Stevanin G, Rivaud&#x2010;Pechoux S, Moigneu C, Camuzat A, et al. Contribution of ATXN2 intermediary polyQ expansions in a spectrum of neurodegenerative disorders. Neurology 2014;83:990&#x2013;995.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4162303</ArticleId><ArticleId IdType="pubmed">25098532</ArticleId></ArticleIdList></Reference><Reference><Citation>Bigot A, Duddy WJ, Ouandaogo ZG, Negroni E, Mariot V, Ghimbovschi S, et al. Age&#x2010;associated methylation suppresses SPRY1, leading to a failure of re&#x2010;quiescence and loss of the reserve stem cell pool in elderly muscle. Cell Rep 2015;13:1172&#x2013;1182.</Citation><ArticleIdList><ArticleId IdType="pubmed">26526994</ArticleId></ArticleIdList></Reference><Reference><Citation>Jong AY, Wu C&#x2010;H, Li J, Sun J, Fabbri M, Wayne AS, et al. Large&#x2010;scale isolation and cytotoxicity of extracellular vesicles derived from activated human natural killer cells. J Extracell Vesicles 2017;6:1294368. 10.1080/20013078.2017.1294368</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/20013078.2017.1294368</ArticleId><ArticleId IdType="pmc">PMC5345580</ArticleId><ArticleId IdType="pubmed">28326171</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Gall L, Ouandaogo ZG, Anakor E, Connolly O, Butler Browne G, Laine J, et al. Optimized method for extraction of exosomes from human primary muscle cells. Skelet Muscle 2020;10:20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7341622</ArticleId><ArticleId IdType="pubmed">32641118</ArticleId></ArticleIdList></Reference><Reference><Citation>Welton JL, Brennan P, Gurney M, Webber JP, Spary LK, Carton DG, et al. Proteomics analysis of vesicles isolated from plasma and urine of prostate cancer patients using a multiplex, aptamer&#x2010;based protein array. J Extracell Vesicles 2016;5:31209. 10.3402/jev.v5.31209</Citation><ArticleIdList><ArticleId IdType="doi">10.3402/jev.v5.31209</ArticleId><ArticleId IdType="pmc">PMC4929354</ArticleId><ArticleId IdType="pubmed">27363484</ArticleId></ArticleIdList></Reference><Reference><Citation>Welton JL, Loveless S, Stone T, von Ruhland C, Robertson NP, Clayton A. Cerebrospinal fluid extracellular vesicle enrichment for protein biomarker discovery in neurological disease; multiple sclerosis. J Extracell Vesicles 2017;6:1369805. 10.1080/20013078.2017.1369805</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/20013078.2017.1369805</ArticleId><ArticleId IdType="pmc">PMC5614217</ArticleId><ArticleId IdType="pubmed">28959386</ArticleId></ArticleIdList></Reference><Reference><Citation>Maury Y, C&#xf4;me J, Piskorowski RA, Salah&#x2010;Mohellibi N, Chevaleyre V, Peschanski M, et al. Combinatorial analysis of developmental cues efficiently converts human pluripotent stem cells into multiple neuronal subtypes. Nat Biotechnol 2014;33:89&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pubmed">25383599</ArticleId></ArticleIdList></Reference><Reference><Citation>Pradat P&#x2010;F, Dubourg O, de Tapia M, di Scala F, Dupuis L, Lenglet T, et al. Muscle gene expression is a marker of amyotrophic lateral sclerosis severity. Neurodegener Dis 2012;9:38&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">21934272</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamelgarn M, Chen J, Kuang L, Arenas A, Zhai J, Zhu H, et al. Proteomic analysis of FUS interacting proteins provides insights into FUS function and its role in ALS. Biochim Biophys Acta&#x2014;Mol Basis Dis 2016;1862:2004&#x2013;2014.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5055831</ArticleId><ArticleId IdType="pubmed">27460707</ArticleId></ArticleIdList></Reference><Reference><Citation>Freibaum BD, Chitta RK, High AA, Taylor JP. Global analysis of TDP&#x2010;43 interacting proteins reveals strong association with rna splicing and translation machinery. J Proteome Res 2010;9:1104&#x2013;1120.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2897173</ArticleId><ArticleId IdType="pubmed">20020773</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamazaki T, Chen S, Yu Y, Yan B, Haertlein TC, Carrasco MA, et al. FUS&#x2010;SMN protein interactions link the motor neuron diseases ALS and SMA. Cell Rep 2012;2:799&#x2013;806.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3483417</ArticleId><ArticleId IdType="pubmed">23022481</ArticleId></ArticleIdList></Reference><Reference><Citation>Stevens JC, Chia R, Hendriks WT, Bros&#x2010;Facer V, van Minnen J, Martin JE, et al. Modification of superoxide dismutase 1 (SOD1) properties by a GFP tag&#x2014;Implications for research into amyotrophic lateral sclerosis (ALS). PLoS ONE 2010;5:e9541. 10.1371/journal.pone.0009541</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0009541</ArticleId><ArticleId IdType="pmc">PMC2833207</ArticleId><ArticleId IdType="pubmed">20221404</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson BS, McCaffery JM, Lindquist S, Gitler AD. A yeast TDP&#x2010;43 proteinopathy model: exploring the molecular determinants of TDP&#x2010;43 aggregation and cellular toxicity. Proc Natl Acad Sci U S A 2008;105:6439&#x2013;6444.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2359814</ArticleId><ArticleId IdType="pubmed">18434538</ArticleId></ArticleIdList></Reference><Reference><Citation>Thorley M, Duguez S, Mazza EM, Valsoni S, Bigot A, Mamchaoui K, et al. Skeletal muscle characteristics are preserved in hTERT/cdk4 human myogenic cell lines. Skelet Muscle 2016;6:43.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5146814</ArticleId><ArticleId IdType="pubmed">27931240</ArticleId></ArticleIdList></Reference><Reference><Citation>Volkening K, Keller BA, Leystra&#x2010;Lantz C, Strong MJ. RNA and protein interactors with TDP&#x2010;43 in human spinal&#x2010;cord lysates in amyotrophic lateral sclerosis. J Proteome Res 2018;17:1712&#x2013;1729.</Citation><ArticleIdList><ArticleId IdType="pubmed">29513014</ArticleId></ArticleIdList></Reference><Reference><Citation>Blokhuis AM, Koppers M, Groen EJN, van den Heuvel DMA, Dini Modigliani S, Anink JJ, et al. Comparative interactomics analysis of different ALS&#x2010;associated proteins identifies converging molecular pathways. Acta Neuropathol 2016;132:175&#x2013;196.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4947123</ArticleId><ArticleId IdType="pubmed">27164932</ArticleId></ArticleIdList></Reference><Reference><Citation>Talbot K, Feneberg E, Scaber J, Thompson AG, Turner MR. Amyotrophic lateral sclerosis: the complex path to precision medicine. J Neurol 2018;265:2454&#x2013;2462.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6182683</ArticleId><ArticleId IdType="pubmed">30054789</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajani DK, Walch M, Martinvalet D, Thomas MP, Lieberman J. Alterations in RNA processing during immune&#x2010;mediated programmed cell death. Proc Natl Acad Sci 2012;109:8688&#x2013;8693.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3365155</ArticleId><ArticleId IdType="pubmed">22589304</ArticleId></ArticleIdList></Reference><Reference><Citation>Sproviero D, La Salvia S, Giannini M, Crippa V, Gagliardi S, Bernuzzi S, et al. Pathological proteins are transported by extracellular vesicles of sporadic amyotrophic lateral sclerosis patients. Front Neurosci 2018;12:487.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6060258</ArticleId><ArticleId IdType="pubmed">30072868</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao M, Kim JR, van Bruggen R, Park J. RNA&#x2010;binding proteins in amyotrophic lateral sclerosis. Mol Cells 2018;41:818&#x2013;829.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6182225</ArticleId><ArticleId IdType="pubmed">30157547</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossi S, Serrano A, Gerbino V, Giorgi A, Di Francesco L, Nencini M, et al. Nuclear accumulation of mRNAs underlies G4C2&#x2010;repeat&#x2010;induced translational repression in a cellular model of C9orf72 ALS. J Cell Sci 2015;128:1787&#x2013;1799.</Citation><ArticleIdList><ArticleId IdType="pubmed">25788698</ArticleId></ArticleIdList></Reference><Reference><Citation>Uhl&#xe9;n M, Fagerberg L, Hallstr&#xf6;m BM, Lindskog C, Oksvold P, Mardinoglu A, et al. Proteomics. Tissue&#x2010;based map of the human proteome. Science 2015;347:1260419. 10.1126/science.1260419</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1260419</ArticleId><ArticleId IdType="pubmed">25613900</ArticleId></ArticleIdList></Reference><Reference><Citation>Picchiarelli G, Demestre M, Zuko A, Been M, Higelin J, Dieterl&#xe9; S, et al. FUS&#x2010;mediated regulation of acetylcholine receptor transcription at neuromuscular junctions is compromised in amyotrophic lateral sclerosis. Nat Neurosci 2019;22:1793&#x2013;1805.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6858880</ArticleId><ArticleId IdType="pubmed">31591561</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernardini C, Censi F, Lattanzi W, Barba M, Calcagnini G, Giuliani A, et al. Mitochondrial network genes in the skeletal muscle of amyotrophic lateral sclerosis patients. PLoS ONE 2013;8:e57739. 10.1371/journal.pone.0057739</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0057739</ArticleId><ArticleId IdType="pmc">PMC3585165</ArticleId><ArticleId IdType="pubmed">23469062</ArticleId></ArticleIdList></Reference><Reference><Citation>Scaricamazza S, Salvatori I, Giacovazzo G, Loeffler JP, Ren&#xe8; F, Rosina M, et al. Skeletal&#x2010;muscle metabolic reprogramming in ALS&#x2010;SOD1G93A mice predates disease onset and is a promising therapeutic target. iScience 2020;23:101087. 10.1016/j.isci.2020.101087</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.isci.2020.101087</ArticleId><ArticleId IdType="pmc">PMC7200935</ArticleId><ArticleId IdType="pubmed">32371370</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobrowolny G, Martini M, Scicchitano BM, Romanello V, Boncompagni S, Nicoletti C, et al. Muscle expression of SOD1 G93A triggers the dismantlement of neuromuscular junction via PKC&#x2010;theta. Antioxid Redox Signal 2018;28:1105&#x2013;1119.</Citation><ArticleIdList><ArticleId IdType="pubmed">28931313</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobrowolny G, Aucello M, Rizzuto E, Beccafico S, Mammucari C, Boncompagni S, et al. Skeletal muscle is a primary target of SOD1G93A&#x2010;mediated toxicity. Cell Metab 2008;8:425&#x2013;436.</Citation><ArticleIdList><ArticleId IdType="pubmed">19046573</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong M, Martin LJ. Skeletal muscle&#x2010;restricted expression of human SOD1 causes motor neuron degeneration in transgenic mice. Hum Mol Genet 2010;19:2284&#x2013;2302.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2865380</ArticleId><ArticleId IdType="pubmed">20223753</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller TM, Kim SH, Yamanaka K, Hester M, Umapathi P, Arnson H, et al. Gene transfer demonstrates that muscle is not a primary target for non&#x2010;cell&#x2010;autonomous toxicity in familial amyotrophic lateral sclerosis. Proc Natl Acad Sci 2006;103:19546&#x2013;19551.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1748262</ArticleId><ArticleId IdType="pubmed">17164329</ArticleId></ArticleIdList></Reference><Reference><Citation>Towne C, Raoul C, Schneider BL, Aebischer P. Systemic AAV6 delivery mediating RNA interference against SOD1: neuromuscular transduction does not alter disease progression in fALS mice. Mol Ther 2008;16:1018&#x2013;1025.</Citation><ArticleIdList><ArticleId IdType="pubmed">18414477</ArticleId></ArticleIdList></Reference><Reference><Citation>Gregorevic P, Blankinship MJ, Allen JM, Crawford RW, Meuse L, Miller DG, et al. Systemic delivery of genes to striated muscles using adeno&#x2010;associated viral vectors. Nat Med 2004;10:828&#x2013;834.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1365046</ArticleId><ArticleId IdType="pubmed">15273747</ArticleId></ArticleIdList></Reference><Reference><Citation>von Haehling S, Morley JE, Coats AJS, Anker SD. Ethical guidelines for publishing in the Journal of Cachexia, Sarcopenia and Muscle: update 2021. J Cachexia Sarcopenia Muscle 2021;12:2259&#x2013;2261.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8718061</ArticleId><ArticleId IdType="pubmed">34904399</ArticleId></ArticleIdList></Reference><Reference><Citation>Benkler C, O'Neil AL, Slepian S, Qian F, Weinreb PH, Rubin LL. Aggregated SOD1 causes selective death of cultured human motor neurons. Sci Rep 2018;8:16393.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6219543</ArticleId><ArticleId IdType="pubmed">30401824</ArticleId></ArticleIdList></Reference><Reference><Citation>W&#xe4;chter N, Storch A, Hermann A. Human TDP&#x2010;43 and FUS selectively affect motor neuron maturation and survival in a murine cell model of ALS by non&#x2010;cell&#x2010;autonomous mechanisms. Amyotroph Lateral Scler Frontotemporal Degener 2015;16:431&#x2013;441.</Citation><ArticleIdList><ArticleId IdType="pubmed">26174443</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>